Genetic Technologies (ASX:GTG) has signed IndyCar racing driver Ms. Pippa Mann to promote BREVAGenplus®, the company’s risk assessment test for non-hereditary breast cancer.
Genetic Technologies is continuing its U.S. focused marketing program for BREVAGenplus, with Pippa Mann serving for a second consecutive term as the product’s ambassador and spokesperson.
The test assesses both clinical risk factors and genetic markers known to be associated with non-hereditary breast cancer to determine a woman's five-year risk of developing the disease.
Genetic’s key partnership activities with Pippa Mann this year will include the BREVAGenplus logo represented on her #63 Dale Coyne Racing car and promotional apparel.
She will also participate at select BREVAGenplus oriented events and other promotional activities over the course of 2017.
Pippa Mann is one of only nine female athletes to ever compete in the “Indy 500” and the only female driver to start in the race over the past four consecutive years.
In December 2016, Genetic raised $8.1 million from professional and sophisticated investors in the U.S.
The funds raised will be used to facilitate the company’s expansion requirements in relation to BREVAGenplus and the development of a colorectal cancer risk assessment test.
Breast cancer affects 1 in 8 women in their lifetime. Each year over 240,000 new cases of breast cancer are diagnosed in the U.S.